The application of the PAR1 inhibitor PZ-128 as an anti-metastatic and anti-angiogenic therapeutic agent in melanoma and breast, ovarian, and lung cancer is being reviewed [57, 72–74]. This evidence concerns the gene F2R and melanoma.